|Bid||36.5800 x 1000|
|Ask||36.5900 x 7000|
|Day's range||36.3400 - 36.6900|
|52-week range||31.6700 - 39.4300|
|PE ratio (TTM)||10.37|
|Earnings date||1 May 2018|
|Forward dividend & yield||1.36 (3.74%)|
|1y target est||40.16|
In 4Q17, Jazz Pharmaceuticals’ (JAZZ) Vyxeos (daunorubicin and cytarabine) generated revenues of $24 million compared to $10 million in 3Q17. In fiscal 2017, Vyxeos reported net revenues of $34 million.
Tetraphase Pharmaceuticals (TTPH) is a clinical-stage biopharmaceutical company focused on creating novel antibiotics. These antibiotics treat serious and life-threatening multidrug-resistant infections by using the company’s proprietary chemistry technology. Its lead product candidate is eravacycline, which is being developed as an intravenous antibiotic.
Spark Therapeutics (ONCE) generated revenue of $12 million in 2017 compared to $20.1 million in 2016. Under this collaboration, Spark Therapeutics maintains the responsibility for developing SPK-FIX candidates through Phase 1 and 2 trials. In November 2017, this agreement was amended, and Spark received a $10 million up-front payment and was eligible to receive an additional $15 million.
Spark Therapeutics (ONCE) is a leader in the field of gene therapy. Spark Therapeutics’ pipeline of gene therapy product candidates targets the retina, liver, and the central nervous system. Of the 20 analysts covering Spark Therapeutics in April 2018, four have given the stock “strong buy” recommendations, and ten have given it “buy” recommendations.
Achaogen (AKAO), a late-stage biopharmaceutical company, develops and commercializes antibacterial treatments for MDR (multidrug-resistant) gram-negative infections. Its lead product candidate, plazomicin, targets serious bacterial infections due to MDR Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae, which was identified as a “nightmare bacteria” by the Centers for Disease Control and Prevention in 2013. Of the 12 analysts covering Achaogen in April 2018, five have recommended a “strong buy,” six have recommended a “buy,” and one has recommended a “sell.” The mean rating for the stock is 1.8, and its target price is $21.56.
Hours after markets closed on Bristol-Myers Squibb Co.’s worst day in more than a year, executives used a sugary analogy to explain to Wall Street why the drugmaker’s new cancer treatment would do just ...
Analysts expect Novartis’s (NVS) revenue to rise ~8.8% to $12.6 billion in 1Q18 following growth in operating revenues across all three of its segments during the quarter.
In 4Q17, AbbVie’s (ABBV) AndroGel reported revenue of $140 million, compared with $174 million in 4Q16, reflecting a ~20% decline YoY (year-over-year) and a ~5% decline quarter-over-quarter. In fiscal 2017, AndroGel generated revenue of $577 million, marking a ~14.5% decline YoY.
J&J (JNJ) beats estimates for both earnings and sales in the first quarter of 2018. It maintains the previously issued earnings guidance for 2018 while increasing the sales range.
CymaBay Therapeutics (CBAY) is a clinical-stage biopharmaceutical company focused on the development of innovative therapies for patients with liver disease and other chronic diseases. Of the eight analysts covering CymaBay Therapeutics in April 2018, two analysts have given the stock a “strong buy” rating, and six analysts have given it a “buy” rating. Of the total 22 analysts covering Pfizer (PFE) in April 2018, two analysts have given the stock a “strong buy” rating, and nine analysts have given it a “buy” rating.
One big deal -- and two small ones -- Pfizer could make instead of buying Bristol-Myers Squibb.
Johnson & Johnson (JNJ) reported revenues of $20.2 billion during 4Q17—11.5% growth compared to 4Q16. Wall Street analysts expect Johnson & Johnson to generate earnings per share of $2.00 on revenues of $19.4 billion in 1Q18—9.2% revenue growth compared to $17.8 billion in 1Q17. The revenue growth is expected to be driven by increased sales across all three business segments.
As we discussed earlier, Johnson & Johnson (JNJ) is scheduled to report 9.2% growth in its revenues to $19.4 billion during 1Q18—compared to revenues of $17.8 billion in 1Q17. Johnson & Johnson’s business is divided into three business segments—the Pharmaceuticals segment, the Consumer segment, and the Medical Devices segment. The Pharmaceuticals segment contributes over 45% of Johnson & Johnson’s total revenues. The segment is Johnson & Johnson’s largest revenue contributor.
NEW YORK, April 16, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
Mylan denied reports Friday that it's interested in buying Merck KGaA's consumer health care business, after Reckitt Benckiser and Nestle reportedly dumped their bids.
Novartis (PFE) to buy AveXis for $8.7 billion. Merck's (MRK) Keytruda succeeds in another key lung cancer study. AbbVie's (ABBV) upadacitinib met endpoints in the 4th phase III study from its SELECT program.
Pfizer (PFE) commences dosing in a phase Ib study, evaluating its gene therapy candidate, PF-06939926, for treating five to 12-yearold boys with duchenne muscular dystrophy.
Glaxo (GSK) will divest its rare disease gene therapy drugs to private biotech Orchard Therapeutics in exchange for a 19.9% stake in the company as well as a seat on its board.
Asian stock markets were mostly higher Friday following overnight gains on Wall Street. Risk sentiment returned as the U.S. explores the possibility of returning to trade talks with 11 Pacific countries ...
Dow Jones component Pfizer has no interest in acquiring rival Bristol Myers Squibb — at least not yet, an analyst reportedly said Thursday.
On April 10, 2018, Pfizer (PFE) announced that it has finalized its agreement with biotechnology company Allogene Therapeutics for Pfizer’s allogeneic CAR-T (chimeric antigen receptor T cells) therapy asset portfolio. Pfizer entered into the agreement on April 3, 2018, for the development of cancer cell therapies. According to the terms of the agreement, upon completion of the transaction, Allogene has rights to Pfizer’s 16 pre-clinical CAR-T assets.
On April 11, 2018, Pfizer (PFE) stock witnessed a muted performance after its late-stage kidney trial for Inlyta failed to show any statistically significant improvement in disease-free survival compared to the placebo. The Phase III ATLAS trial evaluated the use of Inlyta (axitinib) as an adjuvant treatment for patients at high risk of RCC (renal cell carcinoma) recurrence after a nephrectomy.